JP2023526774A5 - - Google Patents

Info

Publication number
JP2023526774A5
JP2023526774A5 JP2022564820A JP2022564820A JP2023526774A5 JP 2023526774 A5 JP2023526774 A5 JP 2023526774A5 JP 2022564820 A JP2022564820 A JP 2022564820A JP 2022564820 A JP2022564820 A JP 2022564820A JP 2023526774 A5 JP2023526774 A5 JP 2023526774A5
Authority
JP
Japan
Prior art keywords
heavy chain
seq
sequence
polypeptide subunit
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022564820A
Other languages
English (en)
Japanese (ja)
Other versions
JP7625007B2 (ja
JP2023526774A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/029909 external-priority patent/WO2021222578A1/en
Priority to JP2022174143A priority Critical patent/JP7462011B2/ja
Publication of JP2023526774A publication Critical patent/JP2023526774A/ja
Publication of JP2023526774A5 publication Critical patent/JP2023526774A5/ja
Priority to JP2024101154A priority patent/JP2024133522A/ja
Priority to JP2025008258A priority patent/JP2025081315A/ja
Application granted granted Critical
Publication of JP7625007B2 publication Critical patent/JP7625007B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022564820A 2020-04-29 2021-04-29 重鎖定常領域が修飾された多重特異性重鎖抗体 Active JP7625007B2 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2022174143A JP7462011B2 (ja) 2020-04-29 2022-10-31 重鎖定常領域が修飾された多重特異性重鎖抗体
JP2024101154A JP2024133522A (ja) 2020-04-29 2024-06-24 重鎖定常領域が修飾された多重特異性重鎖抗体
JP2025008258A JP2025081315A (ja) 2020-04-29 2025-01-21 重鎖定常領域が修飾された多重特異性重鎖抗体

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063017589P 2020-04-29 2020-04-29
US63/017,589 2020-04-29
US202063108796P 2020-11-02 2020-11-02
US63/108,796 2020-11-02
PCT/US2021/029909 WO2021222578A1 (en) 2020-04-29 2021-04-29 Multispecific heavy chain antibodies with modified heavy chain constant regions

Related Child Applications (3)

Application Number Title Priority Date Filing Date
JP2022174143A Division JP7462011B2 (ja) 2020-04-29 2022-10-31 重鎖定常領域が修飾された多重特異性重鎖抗体
JP2024101154A Division JP2024133522A (ja) 2020-04-29 2024-06-24 重鎖定常領域が修飾された多重特異性重鎖抗体
JP2025008258A Division JP2025081315A (ja) 2020-04-29 2025-01-21 重鎖定常領域が修飾された多重特異性重鎖抗体

Publications (3)

Publication Number Publication Date
JP2023526774A JP2023526774A (ja) 2023-06-23
JP2023526774A5 true JP2023526774A5 (https=) 2023-11-07
JP7625007B2 JP7625007B2 (ja) 2025-01-31

Family

ID=78292536

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2022564820A Active JP7625007B2 (ja) 2020-04-29 2021-04-29 重鎖定常領域が修飾された多重特異性重鎖抗体
JP2022174143A Active JP7462011B2 (ja) 2020-04-29 2022-10-31 重鎖定常領域が修飾された多重特異性重鎖抗体
JP2024101154A Pending JP2024133522A (ja) 2020-04-29 2024-06-24 重鎖定常領域が修飾された多重特異性重鎖抗体
JP2025008258A Pending JP2025081315A (ja) 2020-04-29 2025-01-21 重鎖定常領域が修飾された多重特異性重鎖抗体

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2022174143A Active JP7462011B2 (ja) 2020-04-29 2022-10-31 重鎖定常領域が修飾された多重特異性重鎖抗体
JP2024101154A Pending JP2024133522A (ja) 2020-04-29 2024-06-24 重鎖定常領域が修飾された多重特異性重鎖抗体
JP2025008258A Pending JP2025081315A (ja) 2020-04-29 2025-01-21 重鎖定常領域が修飾された多重特異性重鎖抗体

Country Status (13)

Country Link
US (5) US20230203161A1 (https=)
EP (2) EP4186564A1 (https=)
JP (4) JP7625007B2 (https=)
KR (2) KR20250007022A (https=)
CN (2) CN115715220A (https=)
AU (2) AU2021263448B2 (https=)
CA (1) CA3176792C (https=)
CR (2) CR20250494A (https=)
DO (2) DOP2022000229A (https=)
IL (2) IL297601A (https=)
MX (1) MX2022013453A (https=)
PE (1) PE20230431A1 (https=)
UA (1) UA130700C2 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250175345A (ko) 2016-06-21 2025-12-16 테네오바이오, 인코포레이티드 Cd3 결합 항체
IL322083A (en) 2016-08-24 2025-09-01 Teneobio Inc Non-human transgenic animals that produce modified heavy chain antibodies only
PE20241349A1 (es) * 2016-09-14 2024-07-03 Teneobio Inc Anticuerpos de union a cd3
IL317134A (en) 2016-12-21 2025-01-01 Teneobio Inc An antibody containing only heavy chains that binds a human B-cell maturation antigen, a pharmaceutical composition containing the same, its use in the treatment of B-cell disorders and a method for its preparation
CN110945026B (zh) 2017-06-20 2024-03-19 特纳奥尼股份有限公司 仅有重链的抗bcma抗体
KR20250007003A (ko) 2017-06-20 2025-01-13 테네오바이오, 인코포레이티드 항-bcma 중쇄-단독 항체
BR112020024074A2 (pt) 2018-07-20 2021-02-17 Teneobio, Inc. anticorpos de cadeia pesada com ligação a cd19
WO2020206330A1 (en) * 2019-04-05 2020-10-08 Teneobio, Inc. Heavy chain antibodies binding to psma
CR20210622A (es) 2019-06-14 2022-06-27 Teneobio Inc Anticuerpos multiespecíficos de cadena pesada que se unen a cd22 y cd3
IL297601A (en) * 2020-04-29 2022-12-01 Teneobio Inc Multispecific heavy chain antibodies with modified heavy chain constant regions
EP4611903A1 (en) * 2022-11-01 2025-09-10 TeneoTwo, Inc. Methods of treating non-hodgkin lymphoma
EP4680281A2 (en) * 2023-03-13 2026-01-21 The Trustees Of Columbia University In The City Of New York Compositions and methods for hiv latency reversal
WO2025222102A1 (en) * 2024-04-19 2025-10-23 TeneoTwo, Inc. Therapeutic combinations of acalabrutinib and a multispecific antibody to treat b-cell malignancies

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US6750325B1 (en) 1989-12-21 2004-06-15 Celltech R&D Limited CD3 specific recombinant antibody
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5968509A (en) 1990-10-05 1999-10-19 Btp International Limited Antibodies with binding affinity for the CD3 antigen
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
GB9206422D0 (en) 1992-03-24 1992-05-06 Bolt Sarah L Antibody preparation
US7381803B1 (en) 1992-03-27 2008-06-03 Pdl Biopharma, Inc. Humanized antibodies against CD3
US6066721A (en) 1995-07-06 2000-05-23 Stanford University Method to produce novel polyketides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
JP4046354B2 (ja) 1996-03-18 2008-02-13 ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
ATE299938T1 (de) 1997-05-02 2005-08-15 Genentech Inc Ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen
SI1642972T1 (sl) 1999-01-07 2010-05-31 Zymogenetics Inc Terapevtske uporabe BR X topnih receptorjev
US6326175B1 (en) 1999-07-13 2001-12-04 Incyte Pharmaceuticals, Inc. Methods and compositions for producing full length cDNA libraries
CN100447244C (zh) 1999-08-17 2008-12-31 比奥根艾迪克Ma公司 Baff受体(bcma),一种免疫调节剂
UA74798C2 (uk) 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
WO2001024812A1 (en) 1999-10-06 2001-04-12 N.V. Nutricia USE OF TRANSFORMING GROWTH FACTOR β AND GROWTH FACTORS IN THE TREATMENT AND PREVENTION OF DISEASES OF THE INTESTINAL MUCOSA
WO2001087977A2 (en) 2000-05-12 2001-11-22 Amgen Inc. Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci
US20020066516A1 (en) 2000-12-01 2002-06-06 Cornell Stephen W. Mechanism for attaching a lifter to a straw and method therefor
WO2002066516A2 (en) 2001-02-20 2002-08-29 Zymogenetics, Inc. Antibodies that bind both bcma and taci
CN1195779C (zh) 2001-05-24 2005-04-06 中国科学院遗传与发育生物学研究所 抗人卵巢癌抗人cd3双特异性抗体
GB0115256D0 (en) 2001-06-21 2001-08-15 Babraham Inst Mouse light chain locus
WO2004042017A2 (en) 2002-10-31 2004-05-21 Genentech, Inc. Methods and compositions for increasing antibody production
EP1585768A2 (en) 2003-01-23 2005-10-19 Genentech, Inc. Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
RU2005137325A (ru) 2003-05-31 2006-09-10 Микромет Аг (De) Фармацевтическая композиция, содержащая конструкт, специфичный к ерсам
JP2008501621A (ja) 2003-05-31 2008-01-24 マイクロメット アクツィエン ゲゼルシャフト B細胞関連疾患を処置するための二重特異性抗cd3、抗cd19抗体構築物を含む薬学的組成物
MXPA06004035A (es) 2003-10-16 2006-08-31 Micromet Ag Aglutinantes cd3 de-inmunizados multi-especificos.
US20060008548A1 (en) 2003-11-19 2006-01-12 Invista North America S.A R.L. Spinneret plate for producing a bulked continuous filament having a three-sided exterior cross-section and a convex six-sided central void
US7235641B2 (en) 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies
CA2569509C (en) 2004-06-03 2014-08-12 Novimmune S.A. Anti-cd3 antibodies and methods of use thereof
KR101151957B1 (ko) 2004-07-22 2012-06-01 로저 킹돈 크레이그 결합 분자
ES2498794T3 (es) 2005-02-18 2014-09-25 Medarex, L.L.C. Anticuerpos monoclonales contra CD30 que carecen de restos fucosilo
US20160355591A1 (en) 2011-05-02 2016-12-08 Immunomedics, Inc. Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
CN101309703A (zh) 2005-09-12 2008-11-19 诺维莫尼公司 抗cd3抗体组合物
EP1940881B1 (en) 2005-10-11 2016-11-30 Amgen Research (Munich) GmbH Compositions comprising cross-species-specific antibodies and uses thereof
ES2618543T3 (es) 2005-11-23 2017-06-21 Genentech, Inc. Métodos y composiciones relacionados con ensayos de linfocitos B
EP2079483A4 (en) 2006-07-29 2010-10-20 Robert Lamar Bjork Jr BISPECIFIC MONOCLONAL ANTIBODIES (SPECIFIC FOR CD3 AND CD11B) THERAPEUTIC MEDICAMENTS
RU2769948C2 (ru) 2007-04-03 2022-04-11 Эмджен Рисерч (Мьюник) Гмбх CD3-Эпсилон-связывающий домен с межвидовой специфичностью
MX2009010611A (es) 2007-04-03 2010-03-26 Micromet Ag Enlazadores biespecificos, especificos para especies.
RS53008B2 (sr) 2007-04-03 2022-12-30 Amgen Res Munich Gmbh Interspecijski specifičan cd3-epsilon vezujući domen
PL2602323T3 (pl) 2007-06-01 2018-06-29 Open Monoclonal Technology, Inc. Kompozycje i sposoby hamowania endogennych genów immunoglobin i wytwarzania transgenicznych ludzkich przeciwciał typu idiotypowego
CA2720682A1 (en) 2008-04-25 2009-10-29 Zymogenetics, Inc. Levels of bcma protein expression on b cells and use in diagnostic methods
US20100122358A1 (en) 2008-06-06 2010-05-13 Crescendo Biologics Limited H-Chain-only antibodies
US20110293619A1 (en) 2008-10-01 2011-12-01 Micromet Ag CROSS-SPECIES-SPECIFIC PSMAxCD3 BISPECIFIC SINGLE CHAIN ANTIBODY
DK2352763T4 (da) 2008-10-01 2022-10-17 Amgen Res Munich Gmbh Bispecifikke enkeltkædede antistoffer med specificitet for højmolekylære målantigener
EP2352765B1 (en) 2008-10-01 2018-01-03 Amgen Research (Munich) GmbH Cross-species-specific single domain bispecific single chain antibody
EP2370467B1 (en) 2008-10-01 2016-09-07 Amgen Research (Munich) GmbH Cross-species-specific pscaxcd3, cd19xcd3, c-metxcd3, endosialinxcd3, epcamxc d3, igf-1rxcd3 or fapalpha xcd3 bispecific single chain antibody
MX341884B (es) 2009-03-10 2016-09-07 Biogen Ma Inc Anticuerpos anti-antigeno de maduracion de celulas b (bcma).
GB0905023D0 (en) 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
SMT202600080T1 (it) 2010-02-08 2026-03-09 Regeneron Pharma Topo con catena leggera comune
EP3974453A3 (en) 2010-11-16 2022-08-03 Amgen Inc. Agents and methods for treating diseases that correlate with bcma expression
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對bcma之e3以及cd3的結合分子
US20150203591A1 (en) 2012-08-02 2015-07-23 Regeneron Pharmaceuticals, Inc. Mutivalent antigen-binding proteins
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
WO2014068079A1 (en) 2012-11-01 2014-05-08 Max-Delbrück-Centrum für Molekulare Medizin An antibody that binds cd269 (bcma) suitable for use in the treatment of plasma cell diseases such as multiple myeloma and autoimmune diseases
TW201425336A (zh) 2012-12-07 2014-07-01 Amgen Inc Bcma抗原結合蛋白質
PT2931030T (pt) 2012-12-14 2020-08-03 Open Monoclonal Tech Inc Polinucleótidos que codificam anticorpos de roedores com idiótipos humanos e animais que os compreendem
WO2014122143A1 (en) 2013-02-05 2014-08-14 Engmab Ag Method for the selection of antibodies against bcma
UA118029C2 (uk) * 2013-04-29 2018-11-12 Ф. Хоффманн-Ля Рош Аг Модифіковане антитіло, що зв'язується з людським fcrn, й способи його застосування
WO2015095412A1 (en) 2013-12-19 2015-06-25 Zhong Wang Bispecific antibody with two single-domain antigen-binding fragments
DK3105252T3 (da) 2014-02-12 2019-10-14 Michael Uhlin Bispecifikke antistoffer til anvendelse ved stamcelletransplantation
TWI701042B (zh) 2014-03-19 2020-08-11 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
BR112017001183A2 (pt) 2014-07-21 2017-11-28 Novartis Ag tratamento de câncer usando receptor de antígeno quimérico anti-bcma humanizado
CA2955947A1 (en) 2014-07-25 2016-01-28 Cytomx Therapeutics, Inc. Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
DK3221357T3 (da) 2014-11-20 2020-08-10 Hoffmann La Roche Fælles letkæder og fremgangsmåder til anvendelse
EP3023437A1 (en) 2014-11-20 2016-05-25 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
CN105384825B (zh) 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
MX2018002043A (es) * 2015-08-17 2018-07-06 Janssen Pharmaceutica Nv ANTICUERPOS ANTI-BCMA, MOLí‰CULAS DE UNIí“N A ANTíGENOS BIESPECíFICAS QUE SE UNEN A BCMA Y CD3, Y USOS DE ESTOS.
KR20250175345A (ko) 2016-06-21 2025-12-16 테네오바이오, 인코포레이티드 Cd3 결합 항체
PE20241349A1 (es) 2016-09-14 2024-07-03 Teneobio Inc Anticuerpos de union a cd3
GB201621591D0 (en) * 2016-12-19 2017-02-01 Ucb Biopharma Sprl Antibody molecules and method
IL317134A (en) 2016-12-21 2025-01-01 Teneobio Inc An antibody containing only heavy chains that binds a human B-cell maturation antigen, a pharmaceutical composition containing the same, its use in the treatment of B-cell disorders and a method for its preparation
CN110945026B (zh) 2017-06-20 2024-03-19 特纳奥尼股份有限公司 仅有重链的抗bcma抗体
KR20250007003A (ko) 2017-06-20 2025-01-13 테네오바이오, 인코포레이티드 항-bcma 중쇄-단독 항체
ES2928296T3 (es) 2017-06-30 2022-11-16 Us Health Receptores de antígenos quiméricos anti-antígenos de maduración de linfocitos B con dominios humanos
CA3073537A1 (en) * 2017-08-22 2019-02-28 Sanabio, Llc Soluble interferon receptors and uses thereof
KR102820804B1 (ko) * 2017-09-22 2025-06-16 우시 바이올로직스 아일랜드 리미티드 신규한 이중특이적 cd3/cd19 폴리펩티드 복합체
BR112020007002A2 (pt) * 2017-10-10 2020-11-17 Sanofi anticorpos anti-cd38 e métodos de uso
JP2021508479A (ja) 2017-12-27 2021-03-11 テネオバイオ, インコーポレイテッド ヘテロ二量体特異的抗体上のcd3デルタ及びcd3イプシロン
EP3801551A4 (en) 2018-05-24 2022-04-06 Ayala Pharmaceuticals Inc. COMPOSITIONS WITH BISFLUOROALKYL-1,4-BENZODIAZEPINONE COMPOUNDS AND IMMUNOTHERAPEUTICS AND METHODS OF USE THEREOF
BR112020024074A2 (pt) 2018-07-20 2021-02-17 Teneobio, Inc. anticorpos de cadeia pesada com ligação a cd19
SG11202102713TA (en) 2018-09-21 2021-04-29 Teneobio Inc Methods for purifying heterodimeric, multispecific antibodies
JP2022508529A (ja) 2018-09-29 2022-01-19 上海博槿生物科技有限公司 二重標的抗原結合分子
WO2020206330A1 (en) * 2019-04-05 2020-10-08 Teneobio, Inc. Heavy chain antibodies binding to psma
CR20210622A (es) 2019-06-14 2022-06-27 Teneobio Inc Anticuerpos multiespecíficos de cadena pesada que se unen a cd22 y cd3
IL297601A (en) * 2020-04-29 2022-12-01 Teneobio Inc Multispecific heavy chain antibodies with modified heavy chain constant regions

Similar Documents

Publication Publication Date Title
JP2023526774A5 (https=)
JP2021530236A5 (https=)
JP2025111463A5 (https=)
JP2020184996A5 (https=)
JP2023106433A5 (https=)
JP2020528768A5 (https=)
JP2024062992A5 (https=)
JP2022533538A5 (https=)
JP2019536430A5 (https=)
JP2020507328A5 (https=)
JP2021511811A5 (https=)
JP2021510736A5 (https=)
JP2020529410A5 (https=)
JP2022524588A5 (https=)
JP2020507577A5 (https=)
JP2023540526A5 (https=)
JP2023506750A5 (https=)
JP2024537779A5 (https=)
CN113508131B (zh) 人源化抗Aβ单克隆抗体及其应用
JP2024024114A5 (https=)
JP2025016538A5 (https=)
JP2024516098A5 (https=)
JP2023547506A5 (https=)
JP2023537958A5 (https=)
JP2023548529A5 (https=)